KR102642063B1 - 칼슘 채널 억제제 - Google Patents

칼슘 채널 억제제 Download PDF

Info

Publication number
KR102642063B1
KR102642063B1 KR1020197027037A KR20197027037A KR102642063B1 KR 102642063 B1 KR102642063 B1 KR 102642063B1 KR 1020197027037 A KR1020197027037 A KR 1020197027037A KR 20197027037 A KR20197027037 A KR 20197027037A KR 102642063 B1 KR102642063 B1 KR 102642063B1
Authority
KR
South Korea
Prior art keywords
ethyl
methyl
amino
fluoro
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197027037A
Other languages
English (en)
Korean (ko)
Other versions
KR20190130573A (ko
Inventor
토마스 이. 리차드슨
미셸 히긴
티모시 맥도날드
Original Assignee
카비온, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카비온, 인코포레이티드 filed Critical 카비온, 인코포레이티드
Publication of KR20190130573A publication Critical patent/KR20190130573A/ko
Application granted granted Critical
Publication of KR102642063B1 publication Critical patent/KR102642063B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197027037A 2017-02-15 2018-02-15 칼슘 채널 억제제 Active KR102642063B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459355P 2017-02-15 2017-02-15
US62/459,355 2017-02-15
PCT/US2018/018356 WO2018152317A1 (en) 2017-02-15 2018-02-15 Calcium channel inhibitors

Publications (2)

Publication Number Publication Date
KR20190130573A KR20190130573A (ko) 2019-11-22
KR102642063B1 true KR102642063B1 (ko) 2024-03-04

Family

ID=63170001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197027037A Active KR102642063B1 (ko) 2017-02-15 2018-02-15 칼슘 채널 억제제

Country Status (8)

Country Link
US (1) US11130750B2 (https=)
EP (1) EP3585376A4 (https=)
JP (1) JP7134178B2 (https=)
KR (1) KR102642063B1 (https=)
CN (1) CN110545806A (https=)
AU (1) AU2018221722B2 (https=)
CA (1) CA3053781A1 (https=)
WO (1) WO2018152317A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101679262B1 (ko) * 2015-06-08 2016-11-24 한국과학기술연구원 4-이소프로필크로만-3-올 화합물

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
WO2004035000A2 (en) 2002-10-17 2004-04-29 Merck & Co., Inc. Enhancement of sleep with t-type calcium channel antagonists
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
JP4927735B2 (ja) 2004-08-20 2012-05-09 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネル阻害剤
CA2576186A1 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CA2600868A1 (en) 2005-03-09 2006-09-21 Merck & Co., Inc. Quinazolinone t-type calcium channel antagonists
US20100222387A1 (en) 2005-06-23 2010-09-02 Barrow James C 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
CA2611639A1 (en) 2005-06-29 2007-01-04 Merck & Co., Inc. 4-fluoro-piperidine t-type calcium channel antagonists
WO2007007852A1 (ja) 2005-07-14 2007-01-18 Teijin Chemicals Ltd. 発泡樹脂シートおよび液晶表示装置
KR100654328B1 (ko) 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
CA2634147A1 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
MX2008013238A (es) 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
KR100749843B1 (ko) 2006-07-13 2007-08-21 한국과학기술연구원 Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법
KR100969686B1 (ko) 2006-08-07 2010-07-14 한국과학기술연구원 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제
AU2007294763A1 (en) 2006-09-15 2008-03-20 Schering Corporation Treating pain, diabetes, and lipid metabolism disorders
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
AR062790A1 (es) 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
CN101528227A (zh) 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
CN101534818A (zh) 2006-09-15 2009-09-16 先灵公司 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
WO2008117148A1 (en) 2007-03-23 2008-10-02 Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
EP2175725A1 (en) 2007-07-10 2010-04-21 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
KR101079459B1 (ko) 2007-09-14 2011-11-03 이화여자대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물
EP2211864A1 (en) 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
CN101910133A (zh) 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
WO2009056934A1 (en) 2007-10-31 2009-05-07 Pfizer Products Inc. 1,4-dihydronaphthyridine derivatives
KR100917037B1 (ko) 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
US20090270413A1 (en) 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR20100005476A (ko) 2008-07-07 2010-01-15 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법
KR101052620B1 (ko) 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
KR20120030112A (ko) 2009-06-05 2012-03-27 타우 쎄라퓨틱스 엘엘씨 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012094615A2 (en) 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Use of cav3.1 selective t-type calcium channel antagonists
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
SG11201505206WA (en) 2013-01-10 2015-07-30 Tau Therapeutics Llc T-type calcium channel inhibitors for treatment of cancer
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
JP7321097B2 (ja) 2017-04-26 2023-08-04 カビオン・インコーポレイテッド 記憶および認知を改善する、ならびに記憶および認知障害を処置するための方法
JP7326159B2 (ja) 2017-04-26 2023-08-15 カビオン・インコーポレイテッド ドラベ症候群の処置方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101679262B1 (ko) * 2015-06-08 2016-11-24 한국과학기술연구원 4-이소프로필크로만-3-올 화합물

Also Published As

Publication number Publication date
US11130750B2 (en) 2021-09-28
AU2018221722B2 (en) 2022-02-03
JP7134178B2 (ja) 2022-09-09
KR20190130573A (ko) 2019-11-22
AU2018221722A1 (en) 2019-10-03
US20200385367A1 (en) 2020-12-10
WO2018152317A1 (en) 2018-08-23
JP2020507606A (ja) 2020-03-12
EP3585376A4 (en) 2020-11-25
EP3585376A1 (en) 2020-01-01
CA3053781A1 (en) 2018-08-23
CN110545806A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
KR102642063B1 (ko) 칼슘 채널 억제제
JP5269761B2 (ja) ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
AU2011223976B2 (en) Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
KR20210143803A (ko) Tead 전사인자의 신규한 소분자 저해제
US20100249176A1 (en) Heterocycle amide t-type calcium channel antagonists
US8987310B2 (en) Heterocycle amide T-type calcium channel antagonists
JP2006520795A (ja) カンナビノイドレセプターリガンド
RS58786B1 (sr) Novi aminski derivati ili njihove soli kao inhibitori tnf alfa
US9834555B2 (en) Method for treating pain syndrome and other disorders
JP2010524962A (ja) オーロラキナーゼ阻害剤のための創薬法
EP3585772B1 (en) 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
JPWO2018052114A1 (ja) モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用
CN107074856A (zh) CaMKII抑制剂及其用途
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
EA018582B1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
HK1232162B (en) Compounds for treating pain syndrome and other disorders
JP2010229096A (ja) 医薬組成物
NZ723817A (en) Cyclopropylamines as lsd1 inhibitors
HK1231061A1 (en) Cyclopropylamines as lsd1 inhibitors
HK1231061B (en) Cyclopropylamines as lsd1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190916

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230713

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230713

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230927

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230912

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210215

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190920

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240116

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240102

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230927

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230912

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210215

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190920

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240226

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240227

End annual number: 3

Start annual number: 1

PG1601 Publication of registration